Intrauterine infection is one of the main etiologies associated with preterm delivery. Cytokines involved in chorioamnionitis, including IL-l, TNF-a, IL-6, IL-8, and MCPl, activate different pathways that lead to preterm delivery. Antileukinate (AL) is a potent selective IL-8 inhibitor that binds to CXC receptors 1&2 on neutrophils, thereby inhibiting IL-8-induced neutrophil chemotaxis and degranulation. Since CXC receptors 1&2 are critically involved in the pathology of chorioamnionitis, their inhibition with AL may have therapeutic potential. Four timed-pregnant C57BL6 mice groups were studied. LPS group received LPS intraperitoneally on gestational day (GD) 15. The AL group received LPS on GD15 followed immediately by intraperitoneal AL injection and repeated on GDI6, and 17. Control groups received either saline, or no injections. In the LPS group, 90% delivered within 24 hours after LPS administration compared to 20% in the AL group. The LPS group had 85% stillborn compared to 15% in the AL group. Uterine histopathology AL group showed evidence of less inflammatory reaction compared to the LPS group. Uterine tissue and serum from the AL group had a significant reduction of inflammatory cytokines compared with the LPS group. Cytokine levels in brain and lung tissues from surviving pups were not significantly different between the AL and control groups. Our data show that antileukinate significantly delays preterm delivery in a mouse model of chorioamnionitis, and reduces neonatal mortality and morbidity.
. Many of these infections are thought to escape detection because they are either subclinical, or they are caused by cultivation-resistant microbes (6) .
Experimental animal and human studies have investigated many agents/drugs with the goal to delay delivery long enough to administer antenatal corticosteroids, which improve neonatal outcomes to some extent (10) (11) . Tocolysis, after the onset of preterm labor, (using betamimetics, calcium-channel blockers, magnesium, oxytocin antagonists or prostaglandin inhibitors) has only a modest delay in delivery, with prostaglandin inhibitors and calcium channel blockers being most successful in delaying for 48 hours or more (10) . A recent multicenter trial showed that vaginal progesterone has some efficacy for delaying preterm delivery in patients with cervical insufficiency (11). However, meta-analysis of available data for progestogens from the Society of Maternal-Fetal Medicine (12) indicates that it is not associated with prevention of preterm birth in patients with premature rupture of membranes (PROM).
While the current treatments with tocolysis delay preterm delivery by reducing uterine contractility, the fetus continues to be exposed to inflammatory cells and mediators until spontaneous or induced delivery. Antibiotics, used to treat the infection, only reduced the microbial load but did not reduce the inflammatory injury directly. Furthermore, completion of an antibiotic course in preterm PROM does not reduce the maternal IL-6 levels, which corresponds to risk of funisitis in infants (13) . It has also been shown that antibiotic use in preterm PROM remote from term only marginally affects the maternal systemic inflammatory markers (14) .
With microbial invasion of the amniotic cavity, there are marked increased concentrations of the chemokine interleukin-8 (IL-8) (15) . IL-8 and other CXC-chemokines that share the ELR motif [GROa and ENA78 in humans, keratinocyte derived chemokine (KC) and macrophage inflammatory protein 2 (MIP2) in mice], are potent chemoattractants and activators of neutrophils, which act by binding to the CXC-chemokine receptors 1 and 2 (CXCRl, CXCR2) (16, 17) . The fetal inflammatory response syndrome ensues following neutrophil chemotaxis with activated neutrophils and monocytes releasing IL-l~and TNF-a, and activating NF-KB (a transcription factor). This activity in tum stimulates expression of IL-6, which is associated with increased plasma concentrations of the cytokines (18). This associated inflammatory injury has been linked to bronchopulmoanry dysplasia (BPD), periventricularmalacia (PVL), cerebral palsy (CP), and poor neurodevelopmental outcome among newborns (1, 19) .
Many attempts have been made at delaying preterm delivery by using immune-modulators or anti-inflammatory molecules, designed to antagonize specific cytokines to reduce the inflammatory response. Specific strategies have involved the use of Toll-like receptor 4 (TLR-4) antagonists, recombinant human lactoferrin (20) , or matrix metalloproteinase inhibitor (21) . A static magnetic field therapeutic approach has also been used with minimal success (22). Antileukinate (AL) is a hexapeptide chemokine inhibitor with an acetylated amino terminus and an amidated carboxyl terminus (Ac-RRWWCR-NH 2 ) that inhibits the specific binding of IL-8 (and homologues) to CXCR 1 and 2 on the neutrophils. It directly inhibits neutrophil chemotaxis and the subsequent cytokine release at the site of inflammation, thus acting as an immunomodulator (16, 17, 23) . Antileukinate has been used successfully by our group and others to block activation of CXCR-mediated activities in a variety of settings. The studies include: a) inhibition of neutrophil chemotaxis induced by Staphylococcus enterotoxin (16) ; b) attenuation of rat lung allograft rejection (24); c) inhibition of acute lung injury in mice induced by bleomycin (18), hemorrhage (25), or acute pancreatitis (23); d) inhibition of high mobility group box 1 (HMGBl)-induced neutrophil infiltration from lung inflammation (26) .
Intra-amniotic inflammation is a risk factor for adverse pregnancy outcome for patients with preterm labor and intact membranes or patients with preterm PROM. Therefore, we believe that treatment of the inflammatory process is required, and that inhibition of IL-8 activity, as a central path to the induction of inflammation, could be a potential new therapeutic approach. In this study, we hypothesized that inhibition ofCXCRl and CXCR2, using Antileukinate, could delay endotoxin-induced preterm labor and prevent adverse neonatal outcome.
MATERIALS AND METHODS

Animal experiment
All animal procedures were approved by the Institutional Animal Care and Use Committee (lACUC) at the Feinstein Institute for Medical Research, Manhasset, New York. These animals were bred and maintained in the animal facility at the Feinstein Institute. Timed-pregnant C57BL6 mice aged 8-10 weeks were used. The presence of a vaginal plug was documented as day 0 of gestation. Pregnancy was confirmed by finding the vaginal plug and by serial physical examinations. Physical conditions (temperature, humidity etc) and animal activity were monitored daily. Preterm delivery was induced by intraperitoneal injections ofE. coli LPS (055:B5, Sigma-Aldrich Co, St. Louis, MO, USA), on gestational day (GD) 15, at a dose of 50 ug/mouse (average body weight 25 g) (2mg/kg) diluted in 100 ul of normal saline and injected using a 29G needle.
The animals were studied in four groups as shown in Fig Term delivery was defined as delivery after 19 days of gestation (27) . All the animals were observed until spontaneous delivery. The number of live and dead pups was recorded along with the time of delivery. Duration of pregnancy after LPS injection (except for negative control group) was listed as either <24 hours or >24 hours.
Tissue collection
All adult mice and surviving pups were euthanized within 12 h after delivery. Blood was collected from the adult mice (6 h post-injection and post-delivery prior to euthanization), from which serum was obtained and frozen at -20°C. The uteri were collected from adult mice and cut into two halves. One half was flash-frozen in liquid nitrogen for cytokine assays while the second half was stored in 10% buffered formalin solution for histopathology. Surviving pups, were randomly selected for assessment of cytokines. Brain and lung tissues were collected from the selected pups, which were either flash frozen in liquid nitrogen for cytokine assays, or fixed in 10% buffered formalin solution for histopathology.
Cytokine assays
Undiluted serum was used directly for cytokine assays.
The tissue samples were homogenized by cryogenic grinding using mortar and pestle in liquid nitrogen (28), and lysates were obtained by dissolving them using Greenberger Lysis Buffer (GLB) (150 mM NaCl, 15 mM Tris 1 mM MgCl zH20, 1 mM CaCI2, 1% Triton X-100, Protease Inhibitor cocktail) diluted 1:1 with phosphate buffered saline 0.05M pH 7 (PBS) (29). The total protein concentrations in the tissues were measured using Peirce BCA Protein assay kit (Thermo Scientific Pierce Biotechnology, Rockford, IL, USA). Concentrations of IL-l~, TNF-a, IL-6, KC, IL-lO and MCPl were determined by multiplex immunoassay using Cytometric Bead Array kits (BD Biosciences, San Jose, CA, USA) in adult mice serum and uterine tissue lysates, as well as brain and lung tissue lysates from surviving pups as per the manufacturer's instructions. The results were analyzed by flow cytometry using BD FACSArray (BD Biosciences, San Jose, CA, USA) and interpreted with FlowJo software version 10.0.5 (TreeStar, San Carlos, CA, USA).
Histopathological study
The tissue, after fixation for at least 24 h, was processed and embedded in paraffin according to standard procedure. Hematoxylin and eosin sections were cut and prepared for the uteri of all the groups within 12 h after birth. The morphology was checked for inflammatory cells and its damage effects on the uterine tissue. AL and control pups' brains and lungs tissue were also harvested within 12 h after birth and processed with our standard procedures, then stained with hematoxylin and eosin slides for histological examination.
Statistical analysis
Data was tabulated and statistically analyzed using Fisher's exact test. Statistical analysis for cytokine concentrations was performed using one and two-tailed ANOVA with Tukey post hoc test using GraphPad Prism software (GraphPad Software, La Jolla, CA, USA). P values less than 0.05 were considered statistically significant.
RESULTS
Delay inpreterm delivery
LPS group (Positive control): Intraperitoneal injections of LPS alone to dams resulted in preterm delivery in 9 out of 10 dams (90%), with all of them aborting by 16±4 h after LPS injection (Fig. 2) . A total of 67 pups were delivered in the LPS group from all 10 dams. All the pups born prematurely were stillborn or died immediately after delivery (n=57, 85%). One dam from the LPS group continued pregnancy and delivered 10 live pups on GD 19 (Fig.  3 ). Antileukinate group (Test group): Only 2 out of 10 dams (20%) delivered stillborn pups within 24 h after LPS, while preterm delivery was delayed in 8 out of 10 dams (80%) compared to 10% in the LPS group (p<0.05) (Fig. 2) . Among the total of 45 pups delivered from 10 dams in this group, only 7 pups (15%) were stillborn compared to 85% in the LPS group (p<O.OOl) as shown in Fig. 3 . All survived pups were healthy.
Negative controls: All the dams that received 1000 § 100 . . 
Cytokine levels after LPS and AL administration
Post delivery, Dams in the AL group had a significant reduction ofKC (75±llpg/ml), IL6 (87±5 pg/ml), and MCPl (96±8pg/ml), in serum compared with the LPS group (185±36; 245±42; 844±102pg/ ml respectively), (P<0.05) (Fig. 4) . The levels in uterine tissue lysates were similarly reduced but only IL-6 and MCPl (8.2±+3.8 and 92±8pg/g protein in AL vs 33±4. 8 respectively), were statistically significant lower in the AL group (p<O.05) ( Fig. 5 ). Six hours postinjection , TNF-a serum level among dams was significantly elevated in LPS (4285±324), compared to AL (l 254±45) and control (55± 1O), groups. Cytok ine levels in surviving pup brain and lungs in the AL group were not significantly different from those in the control groups (P>O.05) as in Figs. 7 and 8.
H istopathology
Uterin e histopathology III the LPS group showed evidence of severe chorioamnionitis with acute inflammato ry cellular infiltrate (neutrophils), abscess formation and necrosis , while in the AL or control group no evidence of chorioarnnionitis, or any inflammation or damage ( Fig. 9 ) was identified. Histopathological sections of brain and lung tissue of pups from AL, LPS or control did not show any evidence of ischemia or inflammatory damage (not shown). ...... in the test group that received antileukinate which delivered close to term. We used the same dose of LPS, along with 3 administrations of an established dose of antileukinate, based on previous mouse studies (25). Among the dams that received LPS and antileukinate, there was significant delay in delivery with 80% of dams delivering at term (GD 19 or later). Antileukinate inhibits CXC-induced degranulation at concentrations ten-fold lower than needed to stop chemotaxis (17, 31) . Our data show that blocking CXCR 1 and 2 can delay preterm delivery, likely by inhibition of neutrophil chemotaxis and activation, thereby interrupting the cytokine cascade. In similar studies using other molecules, like vaginal progesterone, recombinant lactoferrin and tocolytics (10, 11, 20, 21) , there was maternal mortality and toxicity in some cases, while in our study AL was effective in delaying preterm delivery without using a toxic dose to mothers. IL-6 has been widely accepted as the marker for histological chorioamnionitis (15) , and we showed that by blocking CXCRI and 2, neutrophil infiltration of uterine tissue is reduced ( Fig. 9 A,B ,C,D) and consequently, IL-6 levels were reduced in both the serum and uterine tissue. In the LPS group, there were significant increases in KC, MCPl, and IL-6 serum levels compared to controls, consistent with previous studies (26) . Among dams from the AL group, there was a significant reduction in serum IL-6, KC and MCPl compared to the LPS group, and the levels were not significantly different from control animals.
Cl Con trols
IL-8 and its murine counterpart KC bind to two specific cell surface receptors, CXCRI and CXCR2, both of which are expressed on cells of myeloid lineage, such as mature PMN and monocytes (16) . In mice with inflammatory lung disease induced by LPS, antileukinate was highly effective in blocking early neutrophil trafficking and is associated with a significant decrease in subsequent monocyte accumulation (31). In contrast, pretreatment of mice withantileukinatedidnotaffectpeakalveolarmonocyte accumulation induced by CCL2 alone. This suggests that antileukinate does not block monocyte migration directly. Previously, it has been proposed that early neutrophil recruitment regulates subsequent monocyte accumulation, through the local release of CCL2 (32). Thus, as most of the neutrophil influx precedes monocyte accumulation at a site of inflammation, we believe that the reduced PMN infiltration reduces the monocytes infiltration by "back signaling" from already recruited leukocytes. Thus reducing the neutrophil influx may be doubly beneficial in that it reduces both the immediate inflammatory response as well as subsequent recruitment of other inflammatory myeloid cell types.
The mechanisms of preterm delivery in infection have been investigated extensively but the exact pathway is not well established. One of the widely accepted mechanisms involves activation of the innate immune system by various microorganisms using pattern recognition receptors (e.g.: Toll-like receptors) (33) . This subsequently leads to release of chemokines such as IL-8 (a CXC-chemokine) and MCPI, which induce neutrophil and monocyte infiltration into the uterine tissue, and in turn initiate release of more cytokines mediated by the transcription factor NF-KB. IL-IP and TNF-a are cytokines which are elevated very early in the course of chorioamnionitis and in turn stimulate recruitment of neutrophils and monocytes by a feedforward mechanism. Although the levels of these early cytokines typically wane a few hours later (34) , the consequences of the inflammatory cascade induced by microbial endotoxins, result in secretion of prostaglandins and matrix metalloproteases (MMPs), leading to cervical ripening, dilatation, and eventually preterm delivery (35).
The effect of antileukinate administration on the cytokine profile in our results was similar to the previous studies (17, 25) , showing decreased levels of IL-6 and KC (IL-8 homologue). We also demonstrated similarly reduced neutrophil infiltration into the affected tissues (16, 26) . In our model, there was significant difference in TNF-a level 6 h post-injection, but after birth, IL-IP and TNF-a were not significantly different among the three groups. Both of these cytokines are released in early stage of the inflammation induced by sepsis (35). Indeed, in human experimental endotoxemia, cytokines such as TNF-a are markedly increased 30-45 min after LPS challenge, peaking around 60-120 min (36), and the difference is eliminated with the progression of the inflammatory process.
As a secondary outcome for our study, mortality and morbidity of pups were assessed. Among the antileukinate group, there was a significant increase in the number of surviving pups delivered (85%), compared to the LPS group (15%). All the animals with delayed delivery after LPS and antileukinate injections delivered live pups, whereas all the dams that aborted delivered stillborn! dead pups. It is well known that neonates born to mothers with chorioamnionitis have increased risk of developing CP, PVL, and BPD (I, 19) . Abnormal cytokine profiles with increased levels of TNF-a, IL-I, IL-6, IL-8 have been associated with poor outcomes (19) . In our study, we compared the cytokine levels in the brain and lung tissue lysates of surviving pups in the antileukinate group to the controls and found no significant difference ( Figs. 7 and 8 ). This suggests that antileukinate could protect pups from aborting prematurely and from systemic inflammation, as demonstrated by their cytokine profiles which were similar to controls.
We acknowledge limitations in our study. The samples were collected at different times relative to the initial LPS injection, and dams were observed for spontaneous delivery and not delivered by elective cesarean section. Hence the cytokine profile might not reflect the exact temporal relation to LPS injection in all the groups. In addition, while LPS administration is a well-established murine model for chorioamnionitis, it induces inflammation without the true bacterial infection as in a real life scenario. Despite the limitations, we found a significant delay in preterm delivery and significant reduction in neonatal mortality. Additionally, the cytokine profile of the brain and lung tissues of the surviving pups tended towards normal controls, which explains the marked reduction of morbidity among the survivors.
We conclude that blockade of CXCRI and 2 effectively delays preterm delivery in a mouse model of LPS-induced chorioamnionitis, with concomitant reduction in neonatal mortality. Further studies using antileukinate at different doses and timings, as well as neurodevelopmental studies among surviving pups are required to fully elucidate the potential of CXCR 1 and 2 inhibition in reducing the potentially devastating effects of chorioamnionitis. However, our data suggest that CXC receptors 1 and 2 playa role in the pathology of chorioamnionitis, and their inhibition with the hexapeptide, or a derivative thereof, may have therapeutic potential.
